Xarelto Lawsuit Update: Xarelto Manufacturers Allegedly Concealed Drug’s Dangers

August 27, 2015 – – BloodThinnerHelp.com reports on a new update on Xarelto lawsuits. Recent Xarelto lawsuits allege that the drug’s manufacturers concealed information about the drugs dangers from patients and doctors.

Xarelto’s Advertising Campaigns Mislead Users:

Xarelto sales in the past year have totaled to about $1 billion. The intense marketing campaign that Xarelto’s manufacturers, Bayer AG and Janssen Pharmaceuticals, have implemented since the drug’s release, touting Xarelto as a more convenient alternative to other blood thinners, is responsible for the massive return in sales. What the marketing campaigns fail to mention is the danger that Xarelto carries with it. Xarelto is part of a new group of blood thinners called Xa inhibitors. Xa inhibitors block the chemical in the blood that is responsible for making blood clot, thrombin.

The problem with Xarelto is that there is no antidote to the medication. If a patient suffers an internal bleeding injury, there is no way to stop the bleeding. With other blood thinners, such as Warfarin, doctors can administer vitamin K to help the blood clot, or in more dire situations emergency dialysis can remove the drug from the system, which was the case with Xarelto’s rival, Pradaxa. Neither of these methods will work if the patient is taking Xarelto, which can lead to serious injuries.

Xarelto Lawsuits Allege Bayer Knew of Drug Dangers:

Recent Xarelto lawsuits allege that Bayer knew of the dangers that Xarelto carried and purposely failed to mention it in the drug’s warning labels.
Bayer’s defense against these lawsuits is based on two studies. One of the studies in question was sponsored by Bayer and the other by Janssen, the other company involved in Xarelto lawsuits.

The first study completed was published on September 8, 2011 in the New England Journal of Medicine. The study was called “Rocket-AF”, AF being the condition ‘atrial fibrillation’. The study compared rivaroxaban (the active ingredient in Xarelto) to warfarin in regards to their effectiveness of stroke prevention and how they worked to treat AF. This particular study concluded that there were “no significant differences in rates of major and clinically relevant nonmajor bleeding” between the patients who were treated with warfarin and the patients who received rivaroxaban.

The second study to be published that is part of Bayer’s defense is a comparison between Xarelto and another type of anticoagulant, enoxaparin sodium, a ‘low-molecular weight heparin’. This study is known as “Einstein PE”, the PE referring to pulmonary embolism, and concluded that Xarelto only had a small “superiority for major bleeding” when compared to the other blood thinner.”

Both of these studies failed to discuss the drug’s lack of a reversal agent.
“If Bayer knew about this information, it is unacceptable for them to deliberately withhold it from patients and doctors.” said Marc Goldich, an experienced attorney working on Xarelto lawsuits, “We will help victims seek justice in court.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60003709